Skip to main content
Equibles

Eyal C. Attar

Aprea Therapeutics, Inc. (APRE)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Eyal C. Attar

Vor Biopharma Inc. reported in an 8-K filed April 3, 2025 that Eyal C. Attar resigned as Chief Medical Officer, effective April 18, 2025. The proxy statement of Aprea Therapeutics, Inc. reports total compensation of $1,189,283 for Eyal C. Attar in fiscal 2019, including a base salary of $301,250.

“On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the "Company") of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.”
Vor Biopharma Inc. Form 8-K, filed April 3, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Aprea Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2019 Aprea Therapeutics, Inc. (APRE) $301,250 $1,189,283

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.